Hindering triple negative breast cancer progression by targeting endogenous interleukin‐30 requires IFNγ signaling. Issue 2 (24th January 2021)

• Record Type: Journal Article
• Authors: Sorrentino, Carlo; Ciummo, Stefania Livia; D'Antonio, Luigi; Lanuti, Paola; Abrams, Scott I.; Yin, Zhinan; Lu, Li‐Fan; Di Carlo, Emma
• Is Part Of: Clinical and translational medicine. Volume 11:Issue 2(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-01-24
• Subjects: IFNγ -- interleukin‐30 -- triple negative breast cancer -- tumor microenvironment; Clinical medicine -- Periodicals; Medicine, Experimental -- Periodicals; Medical innovations -- Periodicals; Molecular biology -- Periodicals; Pathology, Molecular -- Periodicals; 616.027
• DOI: 10.1002/ctm2.278
• Languages: English
• ISSNs: 2001-1326

Abstract

Abstract : IL30mRNA expression is associated with the TNBC subtype. IL30 boosts proliferation and migration of TNBC cells and reshapes their immunity gene expression profile. The lack of endogenous IL30 hinders TNBC growth and progression and prolongs host survival. TNBC growth inhibition, due to the lack of endogenous IL30, requires INFγ production by T and NK cells.